J.H.M. Schellens

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

J M Meerum Terwogt, M M Malingré, J. H. Beijnen et al. · PubMed · 1999 · 206 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Heleen A. Bardelmeijer, Jos H. Beijnen, Kenneth R. Brouwer et al. · PubMed · 2000 · 121 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

Peter C.C. Fong, David S. Boss, C. P. Carden et al. · Journal of Clinical Oncology · 2008 · 83 citations

Medicine, Oncology, Pharmacology +17

First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

Timothy A. Yap, David S. Boss, Peter C.C. Fong et al. · Journal of Clinical Oncology · 2007 · 76 citations

Medicine, Oncology, Pharmacology +15

Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results

Rosa T. van der Kaaij, Emma C. E. Wassenaar, Willem J. Koemans et al. · British journal of surgery · 2020 · 54 citations · Full text

Medicine, Oncology, Surgery +11